-
1
-
-
0033599057
-
Disorders of iron metabolism
-
Andrews, N.C., Disorders of iron metabolism. N Engl J Med, 1999, 341(26), 1986-1995.
-
(1999)
N Engl J Med
, vol.341
, Issue.26
, pp. 1986-1995
-
-
Andrews, N.C.1
-
2
-
-
47249142777
-
Iron-sulfur cluster biogenesis and human disease
-
Rouault, T.A.; Tong, W.H., Iron-sulfur cluster biogenesis and human disease. Trends Genet, 2008, 24(8), 398-407.
-
(2008)
Trends Genet
, vol.24
, Issue.8
, pp. 398-407
-
-
Rouault, T.A.1
Tong, W.H.2
-
3
-
-
0021891869
-
The mitochondrial electron transport and oxidative phosphorylation system
-
Hatefi, Y., The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem, 1985, 54, 1015-1069.
-
(1985)
Annu Rev Biochem
, vol.54
, pp. 1015-1069
-
-
Hatefi, Y.1
-
4
-
-
44449145862
-
Redox signaling and cancer: The role of "labile" iron
-
Galaris, D.; Skiada, V.; Barbouti, A., Redox signaling and cancer: the role of "labile" iron. Cancer Lett, 2008, 266(1), 21-29.
-
(2008)
Cancer Lett
, vol.266
, Issue.1
, pp. 21-29
-
-
Galaris, D.1
Skiada, V.2
Barbouti, A.3
-
5
-
-
0034648298
-
The haber-weiss reaction and mechanisms of toxicity
-
Kehrer, J.P., The Haber-Weiss reaction and mechanisms of toxicity. Toxicology, 2000, 149(1), 43-50.
-
(2000)
Toxicology
, vol.149
, Issue.1
, pp. 43-50
-
-
Kehrer, J.P.1
-
6
-
-
35448934759
-
The regulation of cellular iron metabolism
-
Chua, A.C.; Graham, R.M.; Trinder, D.; Olynyk, J.K., The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci, 2007, 44(5-6), 413-459.
-
(2007)
Crit Rev Clin Lab Sci
, vol.44
, Issue.5-6
, pp. 413-459
-
-
Chua, A.C.1
Graham, R.M.2
Trinder, D.3
Olynyk, J.K.4
-
7
-
-
0031567095
-
The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
-
Richardson, D.R.; Ponka, P., The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta, 1997, 1331(1), 1-40.
-
(1997)
Biochim Biophys Acta
, vol.1331
, Issue.1
, pp. 1-40
-
-
Richardson, D.R.1
Ponka, P.2
-
9
-
-
33846691564
-
Iron uptake and metabolism in the new millennium
-
Dunn, L.L.; Rahmanto, Y.S.; Richardson, D.R., Iron uptake and metabolism in the new millennium. Trends Cell Biol, 2007, 17(2), 93-100.
-
(2007)
Trends Cell Biol
, vol.17
, Issue.2
, pp. 93-100
-
-
Dunn, L.L.1
Rahmanto, Y.S.2
Richardson, D.R.3
-
10
-
-
73149092511
-
Optimizing iron chelation strategies in beta-thalassaemia major
-
Porter, J.B., Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev, 2009, 23 Suppl 1, S3-7.
-
(2009)
Blood Rev
, vol.23
, Issue.SUPPL. 1
-
-
Porter, J.B.1
-
11
-
-
29844457587
-
The evolution of iron chelators for the treatment of iron overload disease and cancer
-
Kalinowski, D.S.; Richardson, D.R., The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev, 2005, 57(4), 547-583.
-
(2005)
Pharmacol Rev
, vol.57
, Issue.4
, pp. 547-583
-
-
Kalinowski, D.S.1
Richardson, D.R.2
-
12
-
-
0038663096
-
Iron chelator research: Past, present, and future
-
Tam, T.F.; Leung-Toung, R.; Li, W.; Wang, Y.; Karimian, K.; Spino, M., Iron chelator research: past, present, and future. Curr Med Chem, 2003, 10(12), 983-995.
-
(2003)
Curr Med Chem
, vol.10
, Issue.12
, pp. 983-995
-
-
Tam, T.F.1
Leung-Toung, R.2
Li, W.3
Wang, Y.4
Karimian, K.5
Spino, M.6
-
13
-
-
0042810744
-
Iron chelator chemistry
-
Liu, Z.D.; Liu, D.Y.; Hider, R.C., Iron chelator chemistry. Adv Exp Med Biol, 2002, 509, 141-166.
-
(2002)
Adv Exp Med Biol
, vol.509
, pp. 141-166
-
-
Liu, Z.D.1
Liu, D.Y.2
Hider, R.C.3
-
14
-
-
0023092624
-
Antineuroblastoma activity of desferoxamine in human cell lines
-
Blatt, J.; Stitely, S., Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res, 1987, 47(7), 1749-1750.
-
(1987)
Cancer Res
, vol.47
, Issue.7
, pp. 1749-1750
-
-
Blatt, J.1
Stitely, S.2
-
15
-
-
0023689207
-
Mechanism of antineuroblastoma activity of deferoxamine in vitro
-
Blatt, J.; Taylor, S.R.; Stitely, S., Mechanism of antineuroblastoma activity of deferoxamine in vitro. J Lab Clin Med, 1988, 112(4), 433-436.
-
(1988)
J Lab Clin Med
, vol.112
, Issue.4
, pp. 433-436
-
-
Blatt, J.1
Taylor, S.R.2
Stitely, S.3
-
16
-
-
0023135326
-
In vitro and in vivo effects of deferoxamine in neonatal acute leukemia
-
Estrov, Z.; Tawa, A.; Wang, X.H.; Dube, I.D.; Sulh, H.; Cohen, A.; Gelfand, E.W.; Freedman, M.H., In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood, 1987, 69(3), 757-761.
-
(1987)
Blood
, vol.69
, Issue.3
, pp. 757-761
-
-
Estrov, Z.1
Tawa, A.2
Wang, X.H.3
Dube, I.D.4
Sulh, H.5
Cohen, A.6
Gelfand, E.W.7
Freedman, M.H.8
-
17
-
-
0017127835
-
Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells
-
Hoffbrand, A.V.; Ganeshaguru, K.; Hooton, J.W.; Tattersall, M.H., Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol, 1976, 33(4), 517-526.
-
(1976)
Br J Haematol
, vol.33
, Issue.4
, pp. 517-526
-
-
Hoffbrand, A.V.1
Ganeshaguru, K.2
Hooton, J.W.3
Tattersall, M.H.4
-
18
-
-
0022600935
-
Iron-induced L1210 cell growth: Evidence of a transferrin-independent iron transport
-
Basset, P.; Quesneau, Y.; Zwiller, J., Iron-induced L1210 cell growth: evidence of a transferrin-independent iron transport. Cancer Res, 1986, 46(4 Pt 1), 1644-1647.
-
(1986)
Cancer Res
, vol.46
, Issue.4 PART 1
, pp. 1644-1647
-
-
Basset, P.1
Quesneau, Y.2
Zwiller, J.3
-
19
-
-
0023896498
-
Growth-stimulating effect of ferric citrate on hybridoma cells: Characterization and relation to transferrin function
-
Kovar, J., Growth-stimulating effect of ferric citrate on hybridoma cells: characterization and relation to transferrin function. Hybridoma, 1988, 7(3), 255-263.
-
(1988)
Hybridoma
, vol.7
, Issue.3
, pp. 255-263
-
-
Kovar, J.1
-
20
-
-
0023900767
-
Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis
-
Laskey, J.; Webb, I.; Schulman, H.M.; Ponka, P., Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis. Exp Cell Res, 1988, 176(1), 87-95.
-
(1988)
Exp Cell Res
, vol.176
, Issue.1
, pp. 87-95
-
-
Laskey, J.1
Webb, I.2
Schulman, H.M.3
Ponka, P.4
-
21
-
-
0036118607
-
The iron metabolism of neoplastic cells: Alterations that facilitate proliferation?
-
Kwok, J.C.; Richardson, D.R., The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol, 2002, 42(1), 65-78.
-
(2002)
Crit Rev Oncol Hematol
, vol.42
, Issue.1
, pp. 65-78
-
-
Kwok, J.C.1
Richardson, D.R.2
-
22
-
-
2542504483
-
Structure, function, and mechanism of ribonucleotide reductases
-
Kolberg, M.; Strand, K.R.; Graff, P.; Andersson, K.K., Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta, 2004, 1699(1-2), 1-34.
-
(2004)
Biochim Biophys Acta
, vol.1699
, Issue.1-2
, pp. 1-34
-
-
Kolberg, M.1
Strand, K.R.2
Graff, P.3
Andersson, K.K.4
-
23
-
-
0022260274
-
Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits
-
Engstrom, Y.; Eriksson, S.; Jildevik, I.; Skog, S.; Thelander, L.; Tribukait, B., Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem, 1985, 260(16), 9114-9116.
-
(1985)
J Biol Chem
, vol.260
, Issue.16
, pp. 9114-9116
-
-
Engstrom, Y.1
Eriksson, S.2
Jildevik, I.3
Skog, S.4
Thelander, L.5
Tribukait, B.6
-
24
-
-
0019459845
-
Role of ribonucleotide reductase in expression in the neoplastic program
-
Takeda, E.; Weber, G., Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci, 1981, 28(9), 1007-1014.
-
(1981)
Life Sci
, vol.28
, Issue.9
, pp. 1007-1014
-
-
Takeda, E.1
Weber, G.2
-
25
-
-
0031938457
-
Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential
-
Zhou, B.S.; Tsai, P.; Ker, R.; Tsai, J.; Ho, R.; Yu, J.; Shih, J.; Yen, Y., Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis, 1998, 16(1), 43-49.
-
(1998)
Clin Exp Metastasis
, vol.16
, Issue.1
, pp. 43-49
-
-
Zhou, B.S.1
Tsai, P.2
Ker, R.3
Tsai, J.4
Ho, R.5
Yu, J.6
Shih, J.7
Yen, Y.8
-
26
-
-
0037009846
-
The role of iron in cell cycle progression and the proliferation of neoplastic cells
-
Le, N.T.; Richardson, D.R., The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta, 2002, 1603(1), 31-46.
-
(2002)
Biochim Biophys Acta
, vol.1603
, Issue.1
, pp. 31-46
-
-
Le, N.T.1
Richardson, D.R.2
-
27
-
-
33745823841
-
Ribonucleotide reductase inhibitors and future drug design
-
Shao, J.; Zhou, B.; Chu, B.; Yen, Y., Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets, 2006, 6(5), 409-431.
-
(2006)
Curr Cancer Drug Targets
, vol.6
, Issue.5
, pp. 409-431
-
-
Shao, J.1
Zhou, B.2
Chu, B.3
Yen, Y.4
-
28
-
-
0027380398
-
Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea
-
Nyholm, S.; Thelander, L.; Graslund, A., Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry, 1993, 32(43), 11569-11574.
-
(1993)
Biochemistry
, vol.32
, Issue.43
, pp. 11569-11574
-
-
Nyholm, S.1
Thelander, L.2
Graslund, A.3
-
29
-
-
0031923969
-
Pharmacokinetics and pharmacodynamics of hydroxyurea
-
Gwilt, P.R.; Tracewell, W.G., Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet, 1998, 34(5), 347-358.
-
(1998)
Clin Pharmacokinet
, vol.34
, Issue.5
, pp. 347-358
-
-
Gwilt, P.R.1
Tracewell, W.G.2
-
30
-
-
0018603336
-
Modulation of cell surface iron transferrin receptors by cellular density and state of activation
-
Larrick, J.W.; Cresswell, P., Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct, 1979, 11(4), 579-586.
-
(1979)
J Supramol Struct
, vol.11
, Issue.4
, pp. 579-586
-
-
Larrick, J.W.1
Cresswell, P.2
-
31
-
-
0000302649
-
Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro
-
Trowbridge, I.S.; Lopez, F., Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A, 1982, 79(4), 1175-1179.
-
(1982)
Proc Natl Acad Sci U S A
, vol.79
, Issue.4
, pp. 1175-1179
-
-
Trowbridge, I.S.1
Lopez, F.2
-
32
-
-
0034903090
-
Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene
-
Yang, D.C.; Jiang, X.P.; Elliott, R.L.; Head, J.F., Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Res, 2001, 21(3B), 1777-1787.
-
(2001)
Anticancer Res
, vol.21
, Issue.3 B
, pp. 1777-1787
-
-
Yang, D.C.1
Jiang, X.P.2
Elliott, R.L.3
Head, J.F.4
-
33
-
-
0033566305
-
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation
-
Darnell, G.; Richardson, D.R., The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood, 1999, 94(2), 781-792.
-
(1999)
Blood
, vol.94
, Issue.2
, pp. 781-792
-
-
Darnell, G.1
Richardson, D.R.2
-
34
-
-
4444248453
-
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment
-
Yuan, J.; Lovejoy, D.B.; Richardson, D.R., Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood, 2004, 104(5), 1450-1458.
-
(2004)
Blood
, vol.104
, Issue.5
, pp. 1450-1458
-
-
Yuan, J.1
Lovejoy, D.B.2
Richardson, D.R.3
-
35
-
-
27744528421
-
Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer
-
Richardson, D.R., Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem, 2005, 12(23), 2711-2729.
-
(2005)
Curr Med Chem
, vol.12
, Issue.23
, pp. 2711-2729
-
-
Richardson, D.R.1
-
36
-
-
0035437183
-
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression
-
Gao, J.; Richardson, D.R., The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood, 2001, 98(3), 842-850.
-
(2001)
Blood
, vol.98
, Issue.3
, pp. 842-850
-
-
Gao, J.1
Richardson, D.R.2
-
37
-
-
0030601987
-
Iron deprivation inhibits cyclindependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells
-
Kulp, K.S.; Green, S.L.; Vulliet, P.R., Iron deprivation inhibits cyclindependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp Cell Res, 1996, 229(1), 60-68.
-
(1996)
Exp Cell Res
, vol.229
, Issue.1
, pp. 60-68
-
-
Kulp, K.S.1
Green, S.L.2
Vulliet, P.R.3
-
38
-
-
0028171292
-
G1 phase progression: Cycling on cue
-
Sherr, C.J., G1 phase progression: cycling on cue. Cell, 1994, 79(4), 551-555.
-
(1994)
Cell
, vol.79
, Issue.4
, pp. 551-555
-
-
Sherr, C.J.1
-
39
-
-
34548286520
-
Tuning cell cycle regulation with an iron key
-
Yu, Y.; Kovacevic, Z.; Richardson, D.R., Tuning cell cycle regulation with an iron key. Cell Cycle, 2007, 6(16), 1982-1994.
-
(2007)
Cell Cycle
, vol.6
, Issue.16
, pp. 1982-1994
-
-
Yu, Y.1
Kovacevic, Z.2
Richardson, D.R.3
-
40
-
-
77149125234
-
Iron chelatormediated alterations in gene expression: Identification of novel ironregulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53
-
Saletta, F.; Rahmanto, Y.S.; Noulsri, E.; Richardson, D.R., Iron chelatormediated alterations in gene expression: identification of novel ironregulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol, 2010, 77(3), 443-458.
-
(2010)
Mol Pharmacol
, vol.77
, Issue.3
, pp. 443-458
-
-
Saletta, F.1
Rahmanto, Y.S.2
Noulsri, E.3
Richardson, D.R.4
-
41
-
-
0034003005
-
Stress signals utilize multiple pathways to stabilize p53
-
Ashcroft, M.; Taya, Y.; Vousden, K.H., Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol, 2000, 20(9), 3224-3233.
-
(2000)
Mol Cell Biol
, vol.20
, Issue.9
, pp. 3224-3233
-
-
Ashcroft, M.1
Taya, Y.2
Vousden, K.H.3
-
42
-
-
79955462543
-
Cellular iron-depletion stimulates the JNK and p38 MAP signaling transduction pathways, dissociation of ASK1- thioredoxin and activation of ASK1
-
Yu, Y.; Richardson, D.R., Cellular iron-depletion stimulates the JNK and p38 MAP signaling transduction pathways, dissociation of ASK1- thioredoxin and activation of ASK1. J Biol Chem, 2011, 286(17), 15413-15427.
-
(2011)
J Biol Chem
, vol.286
, Issue.17
, pp. 15413-15427
-
-
Yu, Y.1
Richardson, D.R.2
-
43
-
-
34547137681
-
Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclindependent kinase inhibitor p21CIP1/WAF1 by iron depletion
-
Fu, D.; Richardson, D.R., Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclindependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood, 2007, 110(2), 752-761.
-
(2007)
Blood
, vol.110
, Issue.2
, pp. 752-761
-
-
Fu, D.1
Richardson, D.R.2
-
44
-
-
0742304154
-
Regulation of p27(Kip1) by intracellular iron levels
-
Wang, G.; Miskimins, R.; Miskimins, W.K., Regulation of p27(Kip1) by intracellular iron levels. Biometals, 2004, 17(1), 15-24.
-
(2004)
Biometals
, vol.17
, Issue.1
, pp. 15-24
-
-
Wang, G.1
Miskimins, R.2
Miskimins, W.K.3
-
45
-
-
10344245574
-
NDRG1 is necessary for p53- dependent apoptosis
-
Stein, S.; Thomas, E.K.; Herzog, B.; Westfall, M.D.; Rocheleau, J.V.; Jackson, R.S., 2nd; Wang, M.; Liang, P., NDRG1 is necessary for p53- dependent apoptosis. J Biol Chem, 2004, 279(47), 48930-48940.
-
(2004)
J Biol Chem
, vol.279
, Issue.47
, pp. 48930-48940
-
-
Stein, S.1
Thomas, E.K.2
Herzog, B.3
Westfall, M.D.4
Rocheleau, J.V.5
Jackson II, R.S.6
Wang, M.7
Liang, P.8
-
46
-
-
0037447321
-
The drg-1 gene suppresses tumor metastasis in prostate cancer
-
Bandyopadhyay, S.; Pai, S.K.; Gross, S.C.; Hirota, S.; Hosobe, S.; Miura, K.; Saito, K.; Commes, T.; Hayashi, S.; Watabe, M.; Watabe, K., The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res, 2003, 63(8), 1731-1736.
-
(2003)
Cancer Res
, vol.63
, Issue.8
, pp. 1731-1736
-
-
Bandyopadhyay, S.1
Pai, S.K.2
Gross, S.C.3
Hirota, S.4
Hosobe, S.5
Miura, K.6
Saito, K.7
Commes, T.8
Hayashi, S.9
Watabe, M.10
Watabe, K.11
-
47
-
-
3342962720
-
Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression
-
Bandyopadhyay, S.; Pai, S.K.; Hirota, S.; Hosobe, S.; Takano, Y.; Saito, K.; Piquemal, D.; Commes, T.; Watabe, M.; Gross, S.C.; Wang, Y.; Ran, S.; Watabe, K., Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene, 2004, 23(33), 5675-5681.
-
(2004)
Oncogene
, vol.23
, Issue.33
, pp. 5675-5681
-
-
Bandyopadhyay, S.1
Pai, S.K.2
Hirota, S.3
Hosobe, S.4
Takano, Y.5
Saito, K.6
Piquemal, D.7
Commes, T.8
Watabe, M.9
Gross, S.C.10
Wang, Y.11
Ran, S.12
Watabe, K.13
-
48
-
-
18244390251
-
Drg1 expression in 131 colorectal liver metastases: Correlation with clinical variables and patient outcomes
-
Shah, M.A.; Kemeny, N.; Hummer, A.; Drobnjak, M.; Motwani, M.; Cordon-Cardo, C.; Gonen, M.; Schwartz, G.K., Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res, 2005, 11(9), 3296-3302.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.9
, pp. 3296-3302
-
-
Shah, M.A.1
Kemeny, N.2
Hummer, A.3
Drobnjak, M.4
Motwani, M.5
Cordon-Cardo, C.6
Gonen, M.7
Schwartz, G.K.8
-
49
-
-
33745700194
-
Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis
-
Maruyama, Y.; Ono, M.; Kawahara, A.; Yokoyama, T.; Basaki, Y.; Kage, M.; Aoyagi, S.; Kinoshita, H.; Kuwano, M., Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res, 2006, 66(12), 6233-6242.
-
(2006)
Cancer Res
, vol.66
, Issue.12
, pp. 6233-6242
-
-
Maruyama, Y.1
Ono, M.2
Kawahara, A.3
Yokoyama, T.4
Basaki, Y.5
Kage, M.6
Aoyagi, S.7
Kinoshita, H.8
Kuwano, M.9
-
50
-
-
79955770381
-
The metastasis suppressor, N-MYC downstream regulated gene 1 (NDRG1), UP-regulates P21 VIA P53-independent mechanisms
-
Kovacevic, Z.; Sivagurunathan, S.; Mangs, H.; Chikhani, S.; Zhang, D.; Richardson, D.R., The metastasis suppressor, N-MYC downstream regulated gene 1 (NDRG1), UP-regulates P21 VIA P53-independent mechanisms. Carcinogenesis, 2011, 32(5), 732-740.
-
(2011)
Carcinogenesis
, vol.32
, Issue.5
, pp. 732-740
-
-
Kovacevic, Z.1
Sivagurunathan, S.2
Mangs, H.3
Chikhani, S.4
Zhang, D.5
Richardson, D.R.6
-
51
-
-
34248583886
-
MAP kinase signalling pathways in cancer
-
Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W., MAP kinase signalling pathways in cancer. Oncogene, 2007, 26(22), 3279-3290.
-
(2007)
Oncogene
, vol.26
, Issue.22
, pp. 3279-3290
-
-
Dhillon, A.S.1
Hagan, S.2
Rath, O.3
Kolch, W.4
-
52
-
-
0033729838
-
Control of the eukaryotic cell cycle by MAP kinase signaling pathways
-
Wilkinson, M.G.; Millar, J.B., Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J, 2000, 14(14), 2147-2157.
-
(2000)
FASEB J
, vol.14
, Issue.14
, pp. 2147-2157
-
-
Wilkinson, M.G.1
Millar, J.B.2
-
53
-
-
0023905712
-
Cloning and expression of two genes of Streptomyces pilosus involved in the biosynthesis of the siderophore desferrioxamine B
-
Schupp, T.; Toupet, C.; Divers, M., Cloning and expression of two genes of Streptomyces pilosus involved in the biosynthesis of the siderophore desferrioxamine B. Gene, 1988, 64(2), 179-188.
-
(1988)
Gene
, vol.64
, Issue.2
, pp. 179-188
-
-
Schupp, T.1
Toupet, C.2
Divers, M.3
-
54
-
-
0042384674
-
Iron chelators and iron toxicity
-
Brittenham, G.M., Iron chelators and iron toxicity. Alcohol, 2003, 30(2), 151-158.
-
(2003)
Alcohol
, vol.30
, Issue.2
, pp. 151-158
-
-
Brittenham, G.M.1
-
55
-
-
7444249085
-
The biochemistry of desferrioxamine and its relation to iron metabolism
-
Keberle, H., The Biochemistry of Desferrioxamine and Its Relation to Iron Metabolism. Ann N Y Acad Sci, 1964, 119, 758-768.
-
(1964)
Ann N y Acad Sci
, vol.119
, pp. 758-768
-
-
Keberle, H.1
-
56
-
-
0036888008
-
Chemical aspects of siderophore mediated iron transport
-
Boukhalfa, H.; Crumbliss, A.L., Chemical aspects of siderophore mediated iron transport. Biometals, 2002, 15(4), 325-339.
-
(2002)
Biometals
, vol.15
, Issue.4
, pp. 325-339
-
-
Boukhalfa, H.1
Crumbliss, A.L.2
-
57
-
-
0028158768
-
The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell
-
Richardson, D.; Ponka, P.; Baker, E., The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res, 1994, 54(3), 685-689.
-
(1994)
Cancer Res
, vol.54
, Issue.3
, pp. 685-689
-
-
Richardson, D.1
Ponka, P.2
Baker, E.3
-
58
-
-
0026575576
-
Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2- hydroxy-1-naphthylaldehyde using the hepatocyte in culture
-
Baker, E.; Richardson, D.; Gross, S.; Ponka, P., Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2- hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology, 1992, 15(3), 492-501.
-
(1992)
Hepatology
, vol.15
, Issue.3
, pp. 492-501
-
-
Baker, E.1
Richardson, D.2
Gross, S.3
Ponka, P.4
-
59
-
-
0032006798
-
Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts
-
Selig, R.A.; White, L.; Gramacho, C.; Sterling-Levis, K.; Fraser, I.W.; Naidoo, D., Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer research, 1998, 58(3), 473-478.
-
(1998)
Cancer Research
, vol.58
, Issue.3
, pp. 473-478
-
-
Selig, R.A.1
White, L.2
Gramacho, C.3
Sterling-Levis, K.4
Fraser, I.W.5
Naidoo, D.6
-
60
-
-
77952557403
-
The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice
-
Zhang, W.J.; Wei, H.; Frei, B., The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med (Maywood), 2010, 235(5), 633-641.
-
(2010)
Exp Biol Med (Maywood)
, vol.235
, Issue.5
, pp. 633-641
-
-
Zhang, W.J.1
Wei, H.2
Frei, B.3
-
61
-
-
0031001278
-
Iron-chelating therapy and the treatment of thalassemia
-
Olivieri, N.F.; Brittenham, G.M., Iron-chelating therapy and the treatment of thalassemia. Blood, 1997, 89(3), 739-761.
-
(1997)
Blood
, vol.89
, Issue.3
, pp. 739-761
-
-
Olivieri, N.F.1
Brittenham, G.M.2
-
62
-
-
0025126032
-
Effects of a single course of deferoxamine in neuroblastoma patients
-
Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M.A.; Helson, L., Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res, 1990, 50(16), 4929-4930.
-
(1990)
Cancer Res
, vol.50
, Issue.16
, pp. 4929-4930
-
-
Donfrancesco, A.1
Deb, G.2
Dominici, C.3
Pileggi, D.4
Castello, M.A.5
Helson, L.6
-
63
-
-
0028585886
-
Deferoxamine in children with recurrent neuroblastoma
-
Blatt, J., Deferoxamine in children with recurrent neuroblastoma. Anticancer Res, 1994, 14(5B), 2109-2112.
-
(1994)
Anticancer Res
, vol.14
, Issue.5 B
, pp. 2109-2112
-
-
Blatt, J.1
-
64
-
-
0029066979
-
Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary results. italian neuroblastoma cooperative group
-
Donfrancesco, A.; De Bernardi, B.; Carli, M.; Mancini, A.; Nigro, M.; De Sio, L.; Casale, F.; Bagnulo, S.; Helson, L.; Deb, G., Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Eur J Cancer, 1995, 31A(4), 612-615.
-
(1995)
Eur J Cancer
, vol.31 A
, Issue.4
, pp. 612-615
-
-
Donfrancesco, A.1
De Bernardi, B.2
Carli, M.3
Mancini, A.4
Nigro, M.5
De Sio, L.6
Casale, F.7
Bagnulo, S.8
Helson, L.9
Deb, G.10
-
65
-
-
3042513348
-
The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes
-
Beraldo, H.; Gambino, D., The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes. Mini Rev Med Chem, 2004, 4(1), 31-39.
-
(2004)
Mini Rev Med Chem
, vol.4
, Issue.1
, pp. 31-39
-
-
Beraldo, H.1
Gambino, D.2
-
66
-
-
0017239192
-
Inhibition of tumor cell transplantability by iron and copper complexes of 5-substituted 2- formylpyridine thiosemicarbazones
-
Antholine, W.E.; Knight, J.M.; Petering, D.H., Inhibition of tumor cell transplantability by iron and copper complexes of 5-substituted 2- formylpyridine thiosemicarbazones. J Med Chem, 1976, 19(2), 339-341.
-
(1976)
J Med Chem
, vol.19
, Issue.2
, pp. 339-341
-
-
Antholine, W.E.1
Knight, J.M.2
Petering, D.H.3
-
67
-
-
69949108747
-
Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors
-
Yu, Y.; Kalinowski, D.S.; Kovacevic, Z.; Siafakas, A.R.; Jansson, P.J.; Stefani, C.; Lovejoy, D.B.; Sharpe, P.C.; Bernhardt, P.V.; Richardson, D.R., Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem, 2009, 52(17), 5271-5294.
-
(2009)
J Med Chem
, vol.52
, Issue.17
, pp. 5271-5294
-
-
Yu, Y.1
Kalinowski, D.S.2
Kovacevic, Z.3
Siafakas, A.R.4
Jansson, P.J.5
Stefani, C.6
Lovejoy, D.B.7
Sharpe, P.C.8
Bernhardt, P.V.9
Richardson, D.R.10
-
68
-
-
0037237032
-
Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311
-
Chaston, T.B.; Lovejoy, D.B.; Watts, R.N.; Richardson, D.R., Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res, 2003, 9(1), 402-414.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.1
, pp. 402-414
-
-
Chaston, T.B.1
Lovejoy, D.B.2
Watts, R.N.3
Richardson, D.R.4
-
69
-
-
33645473324
-
A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase
-
Shao, J.; Zhou, B.; Di Bilio, A.J.; Zhu, L.; Wang, T.; Qi, C.; Shih, J.; Yen, Y., A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther, 2006, 5(3), 586-592.
-
(2006)
Mol Cancer Ther
, vol.5
, Issue.3
, pp. 586-592
-
-
Shao, J.1
Zhou, B.2
Di Bilio, A.J.3
Zhu, L.4
Wang, T.5
Qi, C.6
Shih, J.7
Yen, Y.8
-
70
-
-
33750471953
-
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity
-
Richardson, D.R.; Sharpe, P.C.; Lovejoy, D.B.; Senaratne, D.; Kalinowski, D.S.; Islam, M.; Bernhardt, P.V., Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem, 2006, 49(22), 6510-6521.
-
(2006)
J Med Chem
, vol.49
, Issue.22
, pp. 6510-6521
-
-
Richardson, D.R.1
Sharpe, P.C.2
Lovejoy, D.B.3
Senaratne, D.4
Kalinowski, D.S.5
Islam, M.6
Bernhardt, P.V.7
-
71
-
-
0032832996
-
Triapine (3- aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): An inhibitor of ribonucleotide reductase with antineoplastic activity
-
Finch, R.A.; Liu, M.C.; Cory, A.H.; Cory, J.G.; Sartorelli, A.C., Triapine (3- aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul, 1999, 39, 3-12.
-
(1999)
Adv Enzyme Regul
, vol.39
, pp. 3-12
-
-
Finch, R.A.1
Liu, M.C.2
Cory, A.H.3
Cory, J.G.4
Sartorelli, A.C.5
-
72
-
-
34547562971
-
Design, synthesis, and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents
-
Kalinowski, D.S.; Yu, Y.; Sharpe, P.C.; Islam, M.; Liao, Y.T.; Lovejoy, D.B.; Kumar, N.; Bernhardt, P.V.; Richardson, D.R., Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem, 2007, 50(15), 3716-3729.
-
(2007)
J Med Chem
, vol.50
, Issue.15
, pp. 3716-3729
-
-
Kalinowski, D.S.1
Yu, Y.2
Sharpe, P.C.3
Islam, M.4
Liao, Y.T.5
Lovejoy, D.B.6
Kumar, N.7
Bernhardt, P.V.8
Richardson, D.R.9
-
73
-
-
84961008985
-
Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone
-
Brockman, R.W.; Thomson, J.R.; Bell, M.J.; Skipper, H.E., Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res, 1956, 16(2), 167-170.
-
(1956)
Cancer Res
, vol.16
, Issue.2
, pp. 167-170
-
-
Brockman, R.W.1
Thomson, J.R.2
Bell, M.J.3
Skipper, H.E.4
-
74
-
-
0015362471
-
Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone
-
DeConti, R.C.; Toftness, B.R.; Agrawal, K.C.; Tomchick, R.; Mead, J.A.; Bertino, J.R.; Sartorelli, A.C.; Creasey, W.A., Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res, 1972, 32(7), 1455-1462.
-
(1972)
Cancer Res
, vol.32
, Issue.7
, pp. 1455-1462
-
-
Deconti, R.C.1
Toftness, B.R.2
Agrawal, K.C.3
Tomchick, R.4
Mead, J.A.5
Bertino, J.R.6
Sartorelli, A.C.7
Creasey, W.A.8
-
75
-
-
0029833706
-
The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase
-
Cooper, C.E.; Lynagh, G.R.; Hoyes, K.P.; Hider, R.C.; Cammack, R.; Porter, J.B., The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem, 1996, 271(34), 20291-20299.
-
(1996)
J Biol Chem
, vol.271
, Issue.34
, pp. 20291-20299
-
-
Cooper, C.E.1
Lynagh, G.R.2
Hoyes, K.P.3
Hider, R.C.4
Cammack, R.5
Porter, J.B.6
-
76
-
-
0033975268
-
Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
-
Finch, R.A.; Liu, M.; Grill, S.P.; Rose, W.C.; Loomis, R.; Vasquez, K.M.; Cheng, Y.; Sartorelli, A.C., Triapine (3-aminopyridine-2- carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol, 2000, 59(8), 983-991.
-
(2000)
Biochem Pharmacol
, vol.59
, Issue.8
, pp. 983-991
-
-
Finch, R.A.1
Liu, M.2
Grill, S.P.3
Rose, W.C.4
Loomis, R.5
Vasquez, K.M.6
Cheng, Y.7
Sartorelli, A.C.8
-
77
-
-
0035181433
-
Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: Effect on the R2 subunit of ribonucleotide reductase
-
Green, D.A.; Antholine, W.E.; Wong, S.J.; Richardson, D.R.; Chitambar, C.R., Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res, 2001, 7(11), 3574-3579.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.11
, pp. 3574-3579
-
-
Green, D.A.1
Antholine, W.E.2
Wong, S.J.3
Richardson, D.R.4
Chitambar, C.R.5
-
78
-
-
67650394382
-
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
-
Nutting, C.M.; van Herpen, C.M.; Miah, A.B.; Bhide, S.A.; Machiels, J.P.; Buter, J.; Kelly, C.; de Raucourt, D.; Harrington, K.J., Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol, 2009, 20(7), 1275-1279.
-
(2009)
Ann Oncol
, vol.20
, Issue.7
, pp. 1275-1279
-
-
Nutting, C.M.1
Van Herpen, C.M.2
Miah, A.B.3
Bhide, S.A.4
MacHiels, J.P.5
Buter, J.6
Kelly, C.7
De Raucourt, D.8
Harrington, K.J.9
-
79
-
-
0141455148
-
Phase i and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors
-
Murren, J.; Modiano, M.; Clairmont, C.; Lambert, P.; Savaraj, N.; Doyle, T.; Sznol, M., Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res, 2003, 9(11), 4092-4100.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.11
, pp. 4092-4100
-
-
Murren, J.1
Modiano, M.2
Clairmont, C.3
Lambert, P.4
Savaraj, N.5
Doyle, T.6
Sznol, M.7
-
80
-
-
40549137513
-
A multicenter phase II trial of 3- aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
-
Ma, B.; Goh, B.C.; Tan, E.H.; Lam, K.C.; Soo, R.; Leong, S.S.; Wang, L.Z.; Mo, F.; Chan, A.T.; Zee, B.; Mok, T., A multicenter phase II trial of 3- aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs, 2008, 26(2), 169-173.
-
(2008)
Invest New Drugs
, vol.26
, Issue.2
, pp. 169-173
-
-
Ma, B.1
Goh, B.C.2
Tan, E.H.3
Lam, K.C.4
Soo, R.5
Leong, S.S.6
Wang, L.Z.7
Mo, F.8
Chan, A.T.9
Zee, B.10
Mok, T.11
-
81
-
-
34547687556
-
Phase ii study of triapine in patients with metastatic renal cell carcinoma: A trial of the national cancer institute of canada clinical trials group (ncic ind.161)
-
Knox, J.J.; Hotte, S.J.; Kollmannsberger, C.; Winquist, E.; Fisher, B.; Eisenhauer, E.A., Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs, 2007, 25(5), 471-477.
-
(2007)
Invest New Drugs
, vol.25
, Issue.5
, pp. 471-477
-
-
Knox, J.J.1
Hotte, S.J.2
Kollmannsberger, C.3
Winquist, E.4
Fisher, B.5
Eisenhauer, E.A.6
-
82
-
-
74149093251
-
A phase ii trial of triapine (nsc# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern cooperative oncology group study 1503
-
Traynor, A.M.; Lee, J.W.; Bayer, G.K.; Tate, J.M.; Thomas, S.P.; Mazurczak, M.; Graham, D.L.; Kolesar, J.M.; Schiller, J.H., A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs, 2010, 28(1), 91-97.
-
(2010)
Invest New Drugs
, vol.28
, Issue.1
, pp. 91-97
-
-
Traynor, A.M.1
Lee, J.W.2
Bayer, G.K.3
Tate, J.M.4
Thomas, S.P.5
Mazurczak, M.6
Graham, D.L.7
Kolesar, J.M.8
Schiller, J.H.9
-
83
-
-
0018394556
-
Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent
-
Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O., Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett, 1979, 97(2), 317-321.
-
(1979)
FEBS Lett
, vol.97
, Issue.2
, pp. 317-321
-
-
Ponka, P.1
Borova, J.2
Neuwirt, J.3
Fuchs, O.4
-
84
-
-
0041808760
-
Pyridoxal isonicotinoyl hydrazone and its analogues
-
Buss, J.L.; Hermes-Lima, M.; Ponka, P., Pyridoxal isonicotinoyl hydrazone and its analogues. Adv Exp Med Biol, 2002, 509, 205-229.
-
(2002)
Adv Exp Med Biol
, vol.509
, pp. 205-229
-
-
Buss, J.L.1
Hermes-Lima, M.2
Ponka, P.3
-
85
-
-
0037114461
-
Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes
-
Buss, J.L.; Arduini, E.; Ponka, P., Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes. Biochem Pharmacol, 2002, 64(12), 1689-1701.
-
(2002)
Biochem Pharmacol
, vol.64
, Issue.12
, pp. 1689-1701
-
-
Buss, J.L.1
Arduini, E.2
Ponka, P.3
-
86
-
-
0028891974
-
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents
-
Richardson, D.R.; Tran, E.H.; Ponka, P., The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 1995, 86(11), 4295-4306.
-
(1995)
Blood
, vol.86
, Issue.11
, pp. 4295-4306
-
-
Richardson, D.R.1
Tran, E.H.2
Ponka, P.3
-
87
-
-
0018567483
-
Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone
-
Hoy, T.; Humphrys, J.; Jacobs, A.; Williams, A.; Ponka, P., Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol, 1979, 43(3), 443-449.
-
(1979)
Br J Haematol
, vol.43
, Issue.3
, pp. 443-449
-
-
Hoy, T.1
Humphrys, J.2
Jacobs, A.3
Williams, A.4
Ponka, P.5
-
88
-
-
0032771646
-
Crystal and molecular structure of 2- hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: An iron chelator with anti-tumour activity
-
Richardson, D.R.; Bernhardt, P.V., Crystal and molecular structure of 2- hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem, 1999, 4(3), 266-273.
-
(1999)
J Biol Inorg Chem
, vol.4
, Issue.3
, pp. 266-273
-
-
Richardson, D.R.1
Bernhardt, P.V.2
-
89
-
-
33748784061
-
Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death
-
Yiakouvaki, A.; Savovic, J.; Al-Qenaei, A.; Dowden, J.; Pourzand, C., Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death. J Invest Dermatol, 2006, 126(10), 2287-2295.
-
(2006)
J Invest Dermatol
, vol.126
, Issue.10
, pp. 2287-2295
-
-
Yiakouvaki, A.1
Savovic, J.2
Al-Qenaei, A.3
Dowden, J.4
Pourzand, C.5
-
90
-
-
58149479414
-
Treatment of iron overload in thalassemia
-
Cianciulli, P., Treatment of iron overload in thalassemia. Pediatr Endocrinol Rev, 2008, 6 Suppl 1, 208-213.
-
(2008)
Pediatr Endocrinol Rev
, vol.6
, Issue.SUPPL. 1
, pp. 208-213
-
-
Cianciulli, P.1
-
91
-
-
33745261785
-
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox
-
Chantrel-Groussard, K.; Gaboriau, F.; Pasdeloup, N.; Havouis, R.; Nick, H.; Pierre, J.L.; Brissot, P.; Lescoat, G., The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur J Pharmacol, 2006, 541(3), 129-137.
-
(2006)
Eur J Pharmacol
, vol.541
, Issue.3
, pp. 129-137
-
-
Chantrel-Groussard, K.1
Gaboriau, F.2
Pasdeloup, N.3
Havouis, R.4
Nick, H.5
Pierre, J.L.6
Brissot, P.7
Lescoat, G.8
-
92
-
-
77956049342
-
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
-
Messa, E.; Carturan, S.; Maffe, C.; Pautasso, M.; Bracco, E.; Roetto, A.; Messa, F.; Arruga, F.; Defilippi, I.; Rosso, V.; Zanone, C.; Rotolo, A.; Greco, E.; Pellegrino, R.M.; Alberti, D.; Saglio, G.; Cilloni, D., Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica, 2010, 95(8), 1308-1316.
-
(2010)
Haematologica
, vol.95
, Issue.8
, pp. 1308-1316
-
-
Messa, E.1
Carturan, S.2
Maffe, C.3
Pautasso, M.4
Bracco, E.5
Roetto, A.6
Messa, F.7
Arruga, F.8
Defilippi, I.9
Rosso, V.10
Zanone, C.11
Rotolo, A.12
Greco, E.13
Pellegrino, R.M.14
Alberti, D.15
Saglio, G.16
Cilloni, D.17
-
93
-
-
0035886024
-
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells
-
Guzman, M.L.; Neering, S.J.; Upchurch, D.; Grimes, B.; Howard, D.S.; Rizzieri, D.A.; Luger, S.M.; Jordan, C.T., Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 2001, 98(8), 2301-2307.
-
(2001)
Blood
, vol.98
, Issue.8
, pp. 2301-2307
-
-
Guzman, M.L.1
Neering, S.J.2
Upchurch, D.3
Grimes, B.4
Howard, D.S.5
Rizzieri, D.A.6
Luger, S.M.7
Jordan, C.T.8
-
94
-
-
65349129409
-
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1
-
Ohyashiki, J.H.; Kobayashi, C.; Hamamura, R.; Okabe, S.; Tauchi, T.; Ohyashiki, K., The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci, 2009, 100(5), 970-977.
-
(2009)
Cancer Sci
, vol.100
, Issue.5
, pp. 970-977
-
-
Ohyashiki, J.H.1
Kobayashi, C.2
Hamamura, R.3
Okabe, S.4
Tauchi, T.5
Ohyashiki, K.6
-
95
-
-
78650510609
-
MTOR: From growth signal integration to cancer, diabetes and ageing
-
Zoncu, R.; Efeyan, A.; Sabatini, D.M., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol, 2011, 12(1), 21-35.
-
(2011)
Nat Rev Mol Cell Biol
, vol.12
, Issue.1
, pp. 21-35
-
-
Zoncu, R.1
Efeyan, A.2
Sabatini, D.M.3
-
96
-
-
0032529333
-
Tumor cell cytotoxicity of a novel metal chelator
-
Torti, S.V.; Torti, F.M.; Whitman, S.P.; Brechbiel, M.W.; Park, G.; Planalp, R.P., Tumor cell cytotoxicity of a novel metal chelator. Blood, 1998, 92(4), 1384-1389.
-
(1998)
Blood
, vol.92
, Issue.4
, pp. 1384-1389
-
-
Torti, S.V.1
Torti, F.M.2
Whitman, S.P.3
Brechbiel, M.W.4
Park, G.5
Planalp, R.P.6
-
97
-
-
1842785914
-
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator
-
Zhao, R.; Planalp, R.P.; Ma, R.; Greene, B.T.; Jones, B.T.; Brechbiel, M.W.; Torti, F.M.; Torti, S.V., Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem Pharmacol, 2004, 67(9), 1677-1688.
-
(2004)
Biochem Pharmacol
, vol.67
, Issue.9
, pp. 1677-1688
-
-
Zhao, R.1
Planalp, R.P.2
Ma, R.3
Greene, B.T.4
Jones, B.T.5
Brechbiel, M.W.6
Torti, F.M.7
Torti, S.V.8
-
98
-
-
0037014639
-
Mechanisms underlying the cytotoxic effects of Tachpyr - A novel metal chelator
-
Samuni, A.M.; Krishna, M.C.; DeGraff, W.; Russo, A.; Planalp, R.P.; Brechbiel, M.W.; Mitchell, J.B., Mechanisms underlying the cytotoxic effects of Tachpyr - a novel metal chelator. Biochim Biophys Acta, 2002, 1571(3), 211-218.
-
(2002)
Biochim Biophys Acta
, vol.1571
, Issue.3
, pp. 211-218
-
-
Samuni, A.M.1
Krishna, M.C.2
Degraff, W.3
Russo, A.4
Planalp, R.P.5
Brechbiel, M.W.6
Mitchell, J.B.7
-
99
-
-
4744345552
-
Synthesis and potent antitumor activities of novel 1,3,5-cis,cis- triaminocyclohexane Npyridyl derivatives
-
Chong, H.S.; Torti, S.V.; Ma, R.; Torti, F.M.; Brechbiel, M.W., Synthesis and potent antitumor activities of novel 1,3,5-cis,cis-triaminocyclohexane Npyridyl derivatives. J Med Chem, 2004, 47(21), 5230-5234.
-
(2004)
J Med Chem
, vol.47
, Issue.21
, pp. 5230-5234
-
-
Chong, H.S.1
Torti, S.V.2
Ma, R.3
Torti, F.M.4
Brechbiel, M.W.5
-
100
-
-
0037615112
-
Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
-
Trail, P.A.; King, H.D.; Dubowchik, G.M., Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother, 2003, 52(5), 328-337.
-
(2003)
Cancer Immunol Immunother
, vol.52
, Issue.5
, pp. 328-337
-
-
Trail, P.A.1
King, H.D.2
Dubowchik, G.M.3
-
101
-
-
33749515083
-
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
-
Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R., A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A, 2006, 103(40), 14901-14906.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, Issue.40
, pp. 14901-14906
-
-
Whitnall, M.1
Howard, J.2
Ponka, P.3
Richardson, D.R.4
-
102
-
-
80053926659
-
Bp44mT: An orally active chelator of the thiosemicarbazone class with potent anti-tumor efficacy
-
Yu, Y.; Rahmanto, Y.S.; Richardson, D.R., Bp44mT: An orally active chelator of the thiosemicarbazone class with potent anti-tumor efficacy. Br J Pharmacol, 2012, 165(1), 148-166.
-
(2012)
Br J Pharmacol
, vol.165
, Issue.1
, pp. 148-166
-
-
Yu, Y.1
Rahmanto, Y.S.2
Richardson, D.R.3
-
103
-
-
79955391641
-
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
-
Jansson, P.J.; Hawkins, C.L.; Lovejoy, D.B.; Richardson, D.R., The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study. J Inorg Biochem, 2010, 104(11), 1224-1228.
-
(2010)
J Inorg Biochem
, vol.104
, Issue.11
, pp. 1224-1228
-
-
Jansson, P.J.1
Hawkins, C.L.2
Lovejoy, D.B.3
Richardson, D.R.4
-
104
-
-
79956293094
-
The potent and novel thiosemicarbazone chelators, dp44mt and bp44mt, affect crucial thiol systems required for ribonucleotide reductase activity
-
Yu, Y.; Suryo Rahmanto, Y.; Hawkins, C.L.; Richardson, D.R., The Potent and Novel Thiosemicarbazone Chelators, Dp44mT and Bp44mT, Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity. Mol Pharmacol, 2011, 79(6), 921-931.
-
(2011)
Mol Pharmacol
, vol.79
, Issue.6
, pp. 921-931
-
-
Yu, Y.1
Suryo Rahmanto, Y.2
Hawkins, C.L.3
Richardson, D.R.4
-
105
-
-
0024393963
-
Thioredoxin and glutaredoxin systems
-
Holmgren, A., Thioredoxin and glutaredoxin systems. J Biol Chem, 1989, 264(24), 13963-13966.
-
(1989)
J Biol Chem
, vol.264
, Issue.24
, pp. 13963-13966
-
-
Holmgren, A.1
-
106
-
-
2342447940
-
The cytotoxicity and mechanisms of 1,2-naphthoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells
-
Chen, J.; Huang, Y.W.; Liu, G.; Afrasiabi, Z.; Sinn, E.; Padhye, S.; Ma, Y., The cytotoxicity and mechanisms of 1,2-naphthoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol Appl Pharmacol, 2004, 197(1), 40-48.
-
(2004)
Toxicol Appl Pharmacol
, vol.197
, Issue.1
, pp. 40-48
-
-
Chen, J.1
Huang, Y.W.2
Liu, G.3
Afrasiabi, Z.4
Sinn, E.5
Padhye, S.6
Ma, Y.7
-
107
-
-
59149089078
-
The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells
-
Rao, V.A.; Klein, S.R.; Agama, K.K.; Toyoda, E.; Adachi, N.; Pommier, Y.; Shacter, E.B., The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res, 2009, 69(3), 948-957.
-
(2009)
Cancer Res
, vol.69
, Issue.3
, pp. 948-957
-
-
Rao, V.A.1
Klein, S.R.2
Agama, K.K.3
Toyoda, E.4
Adachi, N.5
Pommier, Y.6
Shacter, E.B.7
-
108
-
-
77951096047
-
A series of alphaheterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity
-
Huang, H.; Chen, Q.; Ku, X.; Meng, L.; Lin, L.; Wang, X.; Zhu, C.; Wang, Y.; Chen, Z.; Li, M.; Jiang, H.; Chen, K.; Ding, J.; Liu, H., A series of alphaheterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity. J Med Chem, 2010, 53(8), 3048-3064.
-
(2010)
J Med Chem
, vol.53
, Issue.8
, pp. 3048-3064
-
-
Huang, H.1
Chen, Q.2
Ku, X.3
Meng, L.4
Lin, L.5
Wang, X.6
Zhu, C.7
Wang, Y.8
Chen, Z.9
Li, M.10
Jiang, H.11
Chen, K.12
Ding, J.13
Liu, H.14
-
109
-
-
33646424730
-
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer
-
Ludwig, J.A.; Szakacs, G.; Martin, S.E.; Chu, B.F.; Cardarelli, C.; Sauna, Z.E.; Caplen, N.J.; Fales, H.M.; Ambudkar, S.V.; Weinstein, J.N.; Gottesman, M.M., Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res, 2006, 66(9), 4808-4815.
-
(2006)
Cancer Res
, vol.66
, Issue.9
, pp. 4808-4815
-
-
Ludwig, J.A.1
Szakacs, G.2
Martin, S.E.3
Chu, B.F.4
Cardarelli, C.5
Sauna, Z.E.6
Caplen, N.J.7
Fales, H.M.8
Ambudkar, S.V.9
Weinstein, J.N.10
Gottesman, M.M.11
-
110
-
-
66249134216
-
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells
-
Hall, M.D.; Salam, N.K.; Hellawell, J.L.; Fales, H.M.; Kensler, C.B.; Ludwig, J.A.; Szakacs, G.; Hibbs, D.E.; Gottesman, M.M., Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem, 2009, 52(10), 3191-3204.
-
(2009)
J Med Chem
, vol.52
, Issue.10
, pp. 3191-3204
-
-
Hall, M.D.1
Salam, N.K.2
Hellawell, J.L.3
Fales, H.M.4
Kensler, C.B.5
Ludwig, J.A.6
Szakacs, G.7
Hibbs, D.E.8
Gottesman, M.M.9
-
111
-
-
36448937511
-
Deferiprone in the treatment of transfusion-dependent thalassemia: A review and perspective
-
Galanello, R., Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag, 2007, 3(5), 795-805.
-
(2007)
Ther Clin Risk Manag
, vol.3
, Issue.5
, pp. 795-805
-
-
Galanello, R.1
-
112
-
-
0022628511
-
Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
-
Olivieri, N.F.; Buncic, J.R.; Chew, E.; Gallant, T.; Harrison, R.V.; Keenan, N.; Logan, W.; Mitchell, D.; Ricci, G.; Skarf, B.; et al., Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med, 1986, 314(14), 869-873.
-
(1986)
N Engl J Med
, vol.314
, Issue.14
, pp. 869-873
-
-
Olivieri, N.F.1
Buncic, J.R.2
Chew, E.3
Gallant, T.4
Harrison, R.V.5
Keenan, N.6
Logan, W.7
Mitchell, D.8
Ricci, G.9
Skarf, B.10
-
113
-
-
0022647410
-
The peripheral smear
-
Clodfelter, R.L., Jr., The peripheral smear. Emerg Med Clin North Am, 1986, 4(1), 59-74.
-
(1986)
Emerg Med Clin North Am
, vol.4
, Issue.1
, pp. 59-74
-
-
Clodfelter Jr., R.L.1
-
114
-
-
0022197562
-
Thrombocytopenia associated with intravenous desferrioxamine
-
Walker, J.A.; Sherman, R.A.; Eisinger, R.P., Thrombocytopenia associated with intravenous desferrioxamine. Am J Kidney Dis, 1985, 6(4), 254-256.
-
(1985)
Am J Kidney Dis
, vol.6
, Issue.4
, pp. 254-256
-
-
Walker, J.A.1
Sherman, R.A.2
Eisinger, R.P.3
-
115
-
-
0028557302
-
Deferiprone-associated myelotoxicity
-
al-Refaie, F.N.; Wonke, B.; Hoffbrand, A.V., Deferiprone-associated myelotoxicity. Eur J Haematol, 1994, 53(5), 298-301.
-
(1994)
Eur J Haematol
, vol.53
, Issue.5
, pp. 298-301
-
-
Al-Refaie, F.N.1
Wonke, B.2
Hoffbrand, A.V.3
-
116
-
-
0023950469
-
In vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitors
-
Estrov, Z.; Cohen, A.; Gelfand, E.W.; Freedman, M.H., In vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitors. Toxicol In Vitro, 1988, 2(2), 131-134.
-
(1988)
Toxicol in Vitro
, vol.2
, Issue.2
, pp. 131-134
-
-
Estrov, Z.1
Cohen, A.2
Gelfand, E.W.3
Freedman, M.H.4
-
117
-
-
77649159219
-
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases
-
Kontoghiorghes, G.J.; Kolnagou, A.; Peng, C.T.; Shah, S.V.; Aessopos, A., Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf, 2010, 9(2), 201-206.
-
(2010)
Expert Opin Drug Saf
, vol.9
, Issue.2
, pp. 201-206
-
-
Kontoghiorghes, G.J.1
Kolnagou, A.2
Peng, C.T.3
Shah, S.V.4
Aessopos, A.5
-
118
-
-
0036068230
-
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients
-
Ceci, A.; Baiardi, P.; Felisi, M.; Cappellini, M.D.; Carnelli, V.; De Sanctis, V.; Galanello, R.; Maggio, A.; Masera, G.; Piga, A.; Schettini, F.; Stefano, I.; Tricta, F., The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol, 2002, 118(1), 330-336.
-
(2002)
Br J Haematol
, vol.118
, Issue.1
, pp. 330-336
-
-
Ceci, A.1
Baiardi, P.2
Felisi, M.3
Cappellini, M.D.4
Carnelli, V.5
De Sanctis, V.6
Galanello, R.7
Maggio, A.8
Masera, G.9
Piga, A.10
Schettini, F.11
Stefano, I.12
Tricta, F.13
-
119
-
-
77955864146
-
Deferiprone
-
Piga, A.; Roggero, S.; Salussolia, I.; Massano, D.; Serra, M.; Longo, F., Deferiprone. Ann N Y Acad Sci, 2010, 1202, 75-78.
-
(2010)
Ann N y Acad Sci
, vol.1202
, pp. 75-78
-
-
Piga, A.1
Roggero, S.2
Salussolia, I.3
Massano, D.4
Serra, M.5
Longo, F.6
-
120
-
-
59249086968
-
Current status in iron chelation in hemoglobinopathies
-
Cappellini, M.D.; Piga, A., Current status in iron chelation in hemoglobinopathies. Curr Mol Med, 2008, 8(7), 663-674.
-
(2008)
Curr Mol Med
, vol.8
, Issue.7
, pp. 663-674
-
-
Cappellini, M.D.1
Piga, A.2
-
121
-
-
77649166873
-
The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: A retrospective analysis
-
Kaloyannidis, P.; Yannaki, E.; Sakellari, I.; Bitzioni, E.; Athanasiadou, A.; Mallouri, D.; Anagnostopoulos, A., The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis. Transplantation, 2010, 89(4), 472-479.
-
(2010)
Transplantation
, vol.89
, Issue.4
, pp. 472-479
-
-
Kaloyannidis, P.1
Yannaki, E.2
Sakellari, I.3
Bitzioni, E.4
Athanasiadou, A.5
Mallouri, D.6
Anagnostopoulos, A.7
-
122
-
-
0023629091
-
Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells
-
Kaplinsky, C.; Estrov, Z.; Freedman, M.H.; Gelfand, E.W.; Cohen, A., Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia, 1987, 1(5), 437-441.
-
(1987)
Leukemia
, vol.1
, Issue.5
, pp. 437-441
-
-
Kaplinsky, C.1
Estrov, Z.2
Freedman, M.H.3
Gelfand, E.W.4
Cohen, A.5
-
123
-
-
0021259518
-
Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation
-
Lederman, H.M.; Cohen, A.; Lee, J.W.; Freedman, M.H.; Gelfand, E.W., Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood, 1984, 64(3), 748-753.
-
(1984)
Blood
, vol.64
, Issue.3
, pp. 748-753
-
-
Lederman, H.M.1
Cohen, A.2
Lee, J.W.3
Freedman, M.H.4
Gelfand, E.W.5
-
124
-
-
0033233243
-
Regulation of mammalian O2 homeostasis by hypoxiainducible factor 1
-
Semenza, G.L., Regulation of mammalian O2 homeostasis by hypoxiainducible factor 1. Annu Rev Cell Dev Biol, 1999, 15, 551-578.
-
(1999)
Annu Rev Cell Dev Biol
, vol.15
, pp. 551-578
-
-
Semenza, G.L.1
-
125
-
-
0035917313
-
HIFalpha targeted for VHLmediated destruction by proline hydroxylation: Implications for O2 sensing
-
Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J.M.; Lane, W.S.; Kaelin, W.G., Jr., HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science, 2001, 292(5516), 464-468.
-
(2001)
Science
, vol.292
, Issue.5516
, pp. 464-468
-
-
Ivan, M.1
Kondo, K.2
Yang, H.3
Kim, W.4
Valiando, J.5
Ohh, M.6
Salic, A.7
Asara, J.M.8
Lane, W.S.9
Kaelin Jr., W.G.10
-
126
-
-
0030859287
-
A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor 1beta is a novel bipartite type recognized by the two components of nuclear pore-targeting complex
-
Eguchi, H.; Ikuta, T.; Tachibana, T.; Yoneda, Y.; Kawajiri, K., A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor 1beta is a novel bipartite type recognized by the two components of nuclear pore-targeting complex. J Biol Chem, 1997, 272(28), 17640-17647.
-
(1997)
J Biol Chem
, vol.272
, Issue.28
, pp. 17640-17647
-
-
Eguchi, H.1
Ikuta, T.2
Tachibana, T.3
Yoneda, Y.4
Kawajiri, K.5
-
127
-
-
0034920196
-
Hypoxia regulation of gene transcription
-
Caro, J., Hypoxia regulation of gene transcription. High Alt Med Biol, 2001, 2(2), 145-154.
-
(2001)
High Alt Med Biol
, vol.2
, Issue.2
, pp. 145-154
-
-
Caro, J.1
-
128
-
-
0032100732
-
HIF-1 alpha is required for solid tumor formation and embryonic vascularization
-
Ryan, H.E.; Lo, J.; Johnson, R.S., HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J, 1998, 17(11), 3005-3015.
-
(1998)
EMBO J
, vol.17
, Issue.11
, pp. 3005-3015
-
-
Ryan, H.E.1
Lo, J.2
Johnson, R.S.3
-
129
-
-
7244239197
-
Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A link between iron metabolism and proliferation
-
Le, N.T.; Richardson, D.R., Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood, 2004, 104(9), 2967-2975.
-
(2004)
Blood
, vol.104
, Issue.9
, pp. 2967-2975
-
-
Le, N.T.1
Richardson, D.R.2
-
130
-
-
0032568150
-
Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha
-
An, W.G.; Kanekal, M.; Simon, M.C.; Maltepe, E.; Blagosklonny, M.V.; Neckers, L.M., Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature, 1998, 392(6674), 405-408.
-
(1998)
Nature
, vol.392
, Issue.6674
, pp. 405-408
-
-
An, W.G.1
Kanekal, M.2
Simon, M.C.3
Maltepe, E.4
Blagosklonny, M.V.5
Neckers, L.M.6
-
131
-
-
21344438419
-
Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1)
-
Greijer, A.E.; van der Groep, P.; Kemming, D.; Shvarts, A.; Semenza, G.L.; Meijer, G.A.; van de Wiel, M.A.; Belien, J.A.; van Diest, P.J.; van der Wall, E., Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol, 2005, 206(3), 291-304.
-
(2005)
J Pathol
, vol.206
, Issue.3
, pp. 291-304
-
-
Greijer, A.E.1
Van Der Groep, P.2
Kemming, D.3
Shvarts, A.4
Semenza, G.L.5
Meijer, G.A.6
Van De Wiel, M.A.7
Belien, J.A.8
Van Diest, P.J.9
Van Der Wall, E.10
-
132
-
-
77956225836
-
The maximum tolerated dose and biologic effects of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
-
Choi, B.S.; Alberti, D.B.; Schelman, W.R.; Kolesar, J.M.; Thomas, J.P.; Marnocha, R.; Eickhoff, J.C.; Ivy, S.P.; Wilding, G.; Holen, K.D., The maximum tolerated dose and biologic effects of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol, 2010, 66(5), 973-980.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, Issue.5
, pp. 973-980
-
-
Choi, B.S.1
Alberti, D.B.2
Schelman, W.R.3
Kolesar, J.M.4
Thomas, J.P.5
Marnocha, R.6
Eickhoff, J.C.7
Ivy, S.P.8
Wilding, G.9
Holen, K.D.10
-
133
-
-
67649383518
-
Deferoxamine mimics the pattern of hypoxia-related injury at the microvasculature
-
Bartolome, S.; Dhillon, N.K.; Buch, S.; Casillan, A.J.; Wood, J.G.; O'Brien- Ladner, A.R., Deferoxamine mimics the pattern of hypoxia-related injury at the microvasculature. Shock, 2009, 31(5), 481-485.
-
(2009)
Shock
, vol.31
, Issue.5
, pp. 481-485
-
-
Bartolome, S.1
Dhillon, N.K.2
Buch, S.3
Casillan, A.J.4
Wood, J.G.5
O'Brien-Ladner, A.R.6
-
134
-
-
0036667557
-
A novel iron chelator that does not induce HIF-1 activity
-
Creighton-Gutteridge, M.; Tyrrell, R.M., A novel iron chelator that does not induce HIF-1 activity. Free Radic Biol Med, 2002, 33(3), 356-363.
-
(2002)
Free Radic Biol Med
, vol.33
, Issue.3
, pp. 356-363
-
-
Creighton-Gutteridge, M.1
Tyrrell, R.M.2
-
135
-
-
0032711332
-
Reduction of ultraviolet light-induced oxidative stress by amino acid-based iron chelators
-
Kitazawa, M.; Iwasaki, K., Reduction of ultraviolet light-induced oxidative stress by amino acid-based iron chelators. Biochim Biophys Acta, 1999, 1473(2-3), 400-408.
-
(1999)
Biochim Biophys Acta
, vol.1473
, Issue.2-3
, pp. 400-408
-
-
Kitazawa, M.1
Iwasaki, K.2
-
136
-
-
42549147608
-
Phase i study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
-
Odenike, O.M.; Larson, R.A.; Gajria, D.; Dolan, M.E.; Delaney, S.M.; Karrison, T.G.; Ratain, M.J.; Stock, W., Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs, 2008, 26(3), 233-239.
-
(2008)
Invest New Drugs
, vol.26
, Issue.3
, pp. 233-239
-
-
Odenike, O.M.1
Larson, R.A.2
Gajria, D.3
Dolan, M.E.4
Delaney, S.M.5
Karrison, T.G.6
Ratain, M.J.7
Stock, W.8
-
137
-
-
56849086028
-
Methemoglobinemia: From diagnosis to treatment
-
do Nascimento, T.S.; Pereira, R.O.; de Mello, H.L.; Costa, J., Methemoglobinemia: from diagnosis to treatment. Rev Bras Anestesiol, 2008, 58(6), 651-664.
-
(2008)
Rev Bras Anestesiol
, vol.58
, Issue.6
, pp. 651-664
-
-
Do Nascimento, T.S.1
Pereira, R.O.2
De Mello, H.L.3
Costa, J.4
-
138
-
-
33947213058
-
Methemoglobinemia
-
Camp, N.E., Methemoglobinemia. J Emerg Nurs, 2007, 33(2), 172-174.
-
(2007)
J Emerg Nurs
, vol.33
, Issue.2
, pp. 172-174
-
-
Camp, N.E.1
-
139
-
-
74549133551
-
Biopreservation of red blood cells - The struggle with hemoglobin oxidation
-
Kanias, T.; Acker, J.P., Biopreservation of red blood cells - the struggle with hemoglobin oxidation. FEBS J, 2010, 277(2), 343-356.
-
(2010)
FEBS J
, vol.277
, Issue.2
, pp. 343-356
-
-
Kanias, T.1
Acker, J.P.2
-
140
-
-
0015502066
-
The generation of superoxide radical during the autoxidation of hemoglobin
-
Misra, H.P.; Fridovich, I., The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem, 1972, 247(21), 6960-6962.
-
(1972)
J Biol Chem
, vol.247
, Issue.21
, pp. 6960-6962
-
-
Misra, H.P.1
Fridovich, I.2
-
141
-
-
0035027754
-
Severe methemoglobinemia on reexposure to benzocaine
-
Udeh, C.; Bittikofer, J.; Sum-Ping, S.T., Severe methemoglobinemia on reexposure to benzocaine. J Clin Anesth, 2001, 13(2), 128-130.
-
(2001)
J Clin Anesth
, vol.13
, Issue.2
, pp. 128-130
-
-
Udeh, C.1
Bittikofer, J.2
Sum-Ping, S.T.3
-
143
-
-
15044364497
-
Aniline derivative-induced methemoglobin in rats
-
Singh, H.; Purnell, E.T., Aniline derivative-induced methemoglobin in rats. J Environ Pathol Toxicol Oncol, 2005, 24(1), 57-65.
-
(2005)
J Environ Pathol Toxicol Oncol
, vol.24
, Issue.1
, pp. 57-65
-
-
Singh, H.1
Purnell, E.T.2
|